Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers

FDA has expanded its approval of rucaparib (Rubraca) as a maintenance therapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer whose tumors shrank after subsequent treatment with a platinum-based chemotherapy.

Cancer Currents: An NCI Cancer Research Blog